Virtual Library
Start Your Search
Yasushi Nagata
Author of
-
+
MTE 29 - Stereotactic Body Radiation Therapy for Early Stage Lung Cancer (Sign Up Required) (ID 578)
- Event: WCLC 2017
- Type: Meet the Expert
- Track: Radiotherapy
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 07:00 - 08:00, Room 502
-
+
MTE 29.01 - Update and Overview of SBRT for Early Stage Lung Cancer (ID 7819)
07:00 - 08:00 | Presenting Author(s): Yasushi Nagata
- Abstract
- Presentation
Abstract:
Stereotactic body radiotherapy (SBRT) is a technique, introduced in the late 1990s. SBRT is a method of using single 10-20Gy of high dose and hypofractionated radiotherapy. Recently, many papers have been published on its clinical results, especially in early stage lung cancer. In Japan as JCOG 0403 clinical trial, between July 2004 and November 2008, 169 patients from 15 institutions were registered. 100 inoperable and 64 operable in total 164 patients were eligible. Of the inoperable 100 patients, the % 3-year OS was 59•9% (95% CI: 49•6% - 68•8%). Grade 3 and 4 toxicities were observed in 10, and 2, respectively. No grade 5 toxicity was observed. Of the 64 operable patients, the % 3-year OS was 76•5% (95% CI: 64•0% - 85•1%). Grade 3 toxicities were observed in 5. No Grades 4 and 5 toxicities were observed. SBRT for stage I NSCLC is effective with low incidences of severe toxicity. This treatment can be considered a standard treatment for inoperable stage I NSCLC. This treatment is promising as an alternative to surgery for operable stage I NSCLC. The current ongoing protocols for lung cancer as JCOG 1408 comparing two different doses、42Gy in 4 fractions and 55Gy in 4 fractions for T1N0M0 and clinically diagnosed lung cancer will be presented. In the world, RTOG 0618 showed a good result of SBRT in the treatment of patients with operable stage I/II NSCLC. RTOG 0915 showed no difference in survival between 48Gy in 4 fractions and 34Gy in a single fraction. In central hilar lung cancer patients, additional attentions are required to avoid serious complications. RTOG 0813 is a Phase I/II study for finding an optimal dose. 55Gy in 5 fractions are their recommended dose. JROSG 10-1 recommended 60Gy in 8 fractions. Optimal dose and fractions are still unknown for centrally located lung tumor. Most updated status of SBRT will also be reviewed.
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
